Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068112 | 1.00 | CTSB (0.58) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL998611 | 1.00 | CTSB (0.58) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL19105358 | 0.93 | CTSB (0.61) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL19105400 | 0.86 | ALDH1A1 (0.56) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL8554945 | 0.85 | ALDH1A1 (0.56) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL28072734 | 0.85 | ALDH1A1 (0.51) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL17085306 | 0.83 | CTSB (0.53) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL27591578 | 0.83 | ALDH1A1 (0.50) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL16368841 | 0.83 | CTSB (0.53) | CTSBALDH1A1TDP1MAPK1L3MBTL1 | |
| SCHEMBL27505465 | 0.83 | CTSB (0.53) | CTSBALDH1A1TDP1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963454-B2 | Compounds and compositions for the treatment of parasitic disease | NOVARTIS AG (CH) | 2018-05-08 | — | — | US | disclosed |
| US-9469645-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-10-18 | — | — | US | disclosed |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-2737927-B1 | Imidazo[1,2a]pyrazines and compositions comprising them for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2016-03-30 | — | — | EP | disclosed |
| EP-2737927-A1 | Imidazo[1,2a]pyrazines and compositions comprising them for the treatment of parasitic diseases | IRM LLC (BM) | 2014-06-04 | — | — | EP | disclosed |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2013-10-24 | — | — | US | disclosed |
| US-8557801-B2 | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (BM) | 2013-10-15 | — | — | US | disclosed |
| CN-102471341-A | Compounds and compositions for the treatment of parasitic diseases | IRM LLC | 2012-05-23 | — | — | CN | disclosed |
| EP-2451814-A2 | FUSED IMIDAZOLES AND COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF PARASITIC DISEASES, SUCH AS E.G. MALARIA | IRM LLC (BM) | 2012-05-16 | — | — | EP | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | CTSB 314/4885ALDH1A1 1414/4885TDP1 4599/4885 |
| US-20160108051-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE | SQLE, SGMS2, SGMS1 | CTSB 193/4885ALDH1A1 2013/4885TDP1 4613/4885 |
| US-20130281403-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, ABCB1, FDPS | CTSB 243/4885ALDH1A1 1800/4885TDP1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.